ClinicalTrials.gg
CompletedNCT01894516Updated Dec 16, 2020Results posted

Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)

A Phase 2 interventional study of GLPG0634 and Placebo in Rheumatoid Arthritis, sponsored by Galapagos NV. Completed at 82 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-16.

Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
287
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing GLPG0634 in Arthritis, Rheumatoid — 4 open to participants now, 4 under way, none of them phase 3. GLPG0634 · Arthritis, Rheumatoid.

Enrollment
9th of 17
287 · median 287
Started
2013
with 1 other
Phase 2
6 of 17
none open now
Registered
4th of 17
by date
Lead sponsor
6 of 17
Galapagos NV

Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, this one is the 9th largest by enrollment, is one of 2 that started in 2013, is one of 6 in phase 2, and was the 4th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 17 studies testing GLPG0634 in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About GLPG0634

GLPG0634: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing GLPG0634 in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

  • Participants suffering from active rheumatoid arthritis who had an inadequate response to methotrexate were evaluated for improvement of disease activity (efficacy) when taking GLPG0634 as monotherapy (3 different doses - 50 milligram (mg), 100 mg and 200 mg once daily) or matching placebo for 24 weeks.
  • During the course of the study, patients were also examined for any side effects that could occur (safety and tolerability), and the amount of GLPG0634 present in the blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood (Pharmacodynamics) were determined. Also, the effects of different doses of GLPG0634 administration on participants' disability, fatigue and quality of life were evaluated.
Read the detailed description
  • Treatment duration was 24 weeks in total.
  • However, at Week 12, all participants on placebo and the participants on the 50 mg dose who had not achieved 20% improvement in swollen joint count (SJC66) and tender joint count (TJC68) were assigned (automatically via interactive web response system (IWRS)) to 100 mg once daily (QD) in a blinded fashion and continued treatment until Week 24.
  • Participants in the other groups maintained their randomized treatment until Week 24.
03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female subjects who are ≥18 years of age on the day of signing ,
  • have a diagnosis of RA since at least 6 months and meeting the 2010 ACR/EULAR criteria of RA and ACR functional class I-III,
  • have ≥6 swollen joints (from a 66-joint count) and

    ≥8 tender joints (from a 68-joint count) at Screening and at Baseline,

  • Screening serum c-reactive protein ≥ 0.7 x upper limit of laboratory normal range (),
  • have shown an inadequate response in terms of either lack of efficacy or toxicity to MTX,
  • have agreed to be washed out from MTX for a period of at least 4 weeks before or during the Screening period.

Exclusion criteria

Exclusion Criteria:

  • current therapy with any non-biological disease modifying anti-rheumatic drug (DMARD), with the exception of antimalarials, which must be at a stable dose for at least 12 weeks prior to Screening,
  • current or previous RA treatment with a biologic DMARD, with the exception of biologic DMARDs: administered in a single clinical study setting, and; more than 6 months prior to Screening (12 months for rituximab or other B cell depleting agents), and; where the biologic DMARD was effective, and if discontinued, this should not be due to lack of efficacy,
  • previous treatment at any time with a cytotoxic agent, other than MTX, before Screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
287 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received GLPG0634 matching placebo capsules, orally, once daily (QD) during Weeks 1 to 12 and GLPG0634 100 milligram (mg) QD during Weeks 13 to 24.

    Drug: Placebo

  • Experimental
    GLPG0634 50 mg QD

    Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.

    Drug: GLPG0634

  • Experimental
    GLPG0634 100 mg QD

    Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.

    Drug: GLPG0634

  • Experimental
    GLPG0634 200 mg QD

    Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.

    Drug: GLPG0634

Interventions

  • GLPG0634 capsules.

  • DrugPlacebo

    Placebo capsules.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12

    The American College of Rheumatology (ACR) response is a measurement of improvement in multiple disease assessment criteria. The ACR20 response is defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in tender TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain visual analog scale (VAS) (taken from the Health Assessment Questionnaire - Disability Index \[HAQ-DI\]), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used (ie, to impute a missing response, the participant was assumed to be a non-responder).

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Achieving an ACR20 Response at Week 24

    ACR20 response was defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used.

    Time frame: Week 24

  2. Percentage of Participants Achieving an ACR50 Response at Weeks 1, 2, 4, 8, 12, and 24

    ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2. Patient's Global Assessment of Disease Activity VAS 3. Physician's Global Assessment of Disease Activity VAS 4. Total HAQ-DI score 5. CRP. Non-responder imputation was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

    Time frame: Weeks 1, 2, 4, 8, 12, and 24

  3. Percentage of Participants Achieving an ACR70 Response at Weeks 1, 2, 4, 8, 12, and 24

    ACR70 response: 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

    Time frame: Weeks 1, 2, 4, 8, 12, and 24

  4. ACR N% Improvement (ACR-N) Response at Weeks 1, 2, 4, 8, 12, and 24

    The ACR-N is the smallest percentage improvement in swollen and tender joints and the median of the remaining 5 core parameters, and is expected to be more sensitive to change than the ACR20, ACR50 or ACR70. It is a number varying between 0 and 100, with higher numbers indicating less severity of symptoms. Last observation carried forward (LOCF) algorithm was used (ie, to impute a missing value, the last preceding nonmissing value was used). All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

    Time frame: Weeks 1, 2, 4, 8, 12, and 24

  5. Percentage of Participants With Disease Activity Score 28 Joints Corrected for CRP (DAS28 (CRP)) European League Against Rheumatism (EULAR) Response at Weeks 1, 2, 4, 8, 12, and 24

    DAS28 (CRP) was categorized into EULAR response categories (none, moderate, good) as follows: None = Actual DAS28 (CRP) ≤ 3.2, \> 3.2 to ≤ 5.1, or \> 5.1 AND Improvement in DAS28 (CRP) from baseline ≤ 6.0 or \> 0.6 to ≤ 1.2; Moderate = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline \> 0.6 to ≤ 1.2, Actual DAS28 (CRP) \> 3.2 to ≤ 5.1 or \> 5.1 AND Improvement in DAS28 (CRP) from baseline \> 1.2, or Actual DAS28 (CRP) \> 3.2 to ≤ 5.1 AND Improvement in DAS28 (CRP) from baseline \> 0.6 to ≤ 1.2; Good = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline \> 1.2. LOCF algorithm was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

    Time frame: Weeks 1, 2, 4, 8, 12, and 24

  6. Percentage of Participants Achieving ACR/EULAR Remission at Weeks 2, 4, 8, 12, and 24

    A participant's disease activity status can be defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and Patient Global Assessment of Disease Activity (cm) are all ≤ 1. Non-responder imputation was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

    Time frame: Weeks 4, 8, 12, and 24

  7. Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 1, 2, 4, 8, 12, and 24

    The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), Physician's Global Assessment of Disease Activity (in cm), and CRP (mg/dL). The SDAI was categorized as follows: • High disease activity: SDAI \> 26 • Moderate disease activity: 11 to 26 • Low disease activity: 3.3 to 11 • Remission: ≤ 3.3. LOCF algorithm was used. The SDAI total score ranges from 0 to approximately 86. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

    Time frame: Baseline and Weeks 1, 2, 4, 8, 12, and 24

  8. Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 1, 2, 4, 8, 12, and 24

    The CDAI is the SDAI modified to exclude CRP and is the sum of the 4 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), and Physician's Global Assessment of Disease Activity (in cm). The CDAI was be categorized as follows: • High disease activity: \> 22 • Moderate disease activity: 10 to 22 • Mild disease activity: 2.8 to 10 • Remission: ≤ 2.8. LOCF algorithm was used. The CDAI total score ranges from 0 to approximately 76. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

    Time frame: Baseline and Weeks 1, 2, 4, 8, 12, and 24

  9. Change From Baseline in Quality of Life Using the Functional Assessment of Chronic Illness Therapy (FACIT) at Weeks 4, 12, and 24

    FACIT-Fatigue scale is a 13-item questionnaire, each scored on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated that are scored reversely), the greater the fatigue. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score), with a higher score indicating a better quality of life. LOCF algorithm was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

    Time frame: Baseline and Weeks 4, 12, and 24

  10. Change From Baseline in Quality of Life Using the Short Form-36 (SF-36) Scores at Weeks 4, 12, and 24

    The SF-36 is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status. Two summary scale scores were computed based on weighted combinations of the 8 domain scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). LOCF algorithm was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

    Time frame: Baseline and Weeks 4, 12, and 24

07

Results

Posted Nov 19, 2020

Participant flow

Participants were enrolled at study sites in Latin America, Europe, United States, and New Zealand. The first participant was screened on 08 October 2013. The last study visit occurred on 29 May 2015.

Period 1 (Baseline up to Week 12)
Participant flow — Period 1 (Baseline up to Week 12)
MilestonePlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QD
Started72727069
Completed65676766
Not completed7533
Withdrew: Other0110
Withdrew: Adverse event and treatment failure2000
Withdrew: Non compliance with the study medication1100
Withdrew: Treatment failure0010
Withdrew: Adverse event2001
Withdrew: Withdrawal by subject2312
Period 2 (Week 13 to Week 24)
Participant flow — Period 2 (Week 13 to Week 24)
MilestonePlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QD
Started05214766
Completed05014265
Not completed0251
Withdrew: Adverse event0231
Withdrew: Withdrawal by subject0020

Outcome measures

PrimaryPercentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12

The American College of Rheumatology (ACR) response is a measurement of improvement in multiple disease assessment criteria. The ACR20 response is defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in tender TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain visual analog scale (VAS) (taken from the Health Assessment Questionnaire - Disability Index \[HAQ-DI\]), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used (ie, to impute a missing response, the participant was assumed to be a non-responder).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12
percentage of participantsPlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QD
Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 1229.266.765.772.5
Statistical analysis
  • Placebo vs GLPG0634 50 mg QD · Regression, Logistic · p = < 0.0001 (P-value has been corrected for multiplicity according to Hommel's closed-testing method.) · Difference in percentage rates: 37.5 · 95% CI 22.4 to 52.6
  • Placebo vs GLPG0634 100 mg QD · Regression, Logistic · p = < 0.0001 (P-value has been corrected for multiplicity according to Hommel's closed-testing method.) · Difference in percentage rates: 36.5 · 95% CI 21.3 to 51.8
  • Placebo vs GLPG0634 200 mg QD · Regression, Logistic · p = < 0.0001 (P-value has been corrected for multiplicity according to Hommel's closed-testing method.) · Difference in percentage rates: 43.3 · 95% CI 28.4 to 58.2
SecondaryPercentage of Participants Achieving an ACR20 Response at Week 24

ACR20 response was defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an ACR20 Response at Week 24
percentage of participantsGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QD
Percentage of Participants Achieving an ACR20 Response at Week 2456.978.666.7
SecondaryPercentage of Participants Achieving an ACR50 Response at Weeks 1, 2, 4, 8, 12, and 24

ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2. Patient's Global Assessment of Disease Activity VAS 3. Physician's Global Assessment of Disease Activity VAS 4. Total HAQ-DI score 5. CRP. Non-responder imputation was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

Time frame:
Weeks 1, 2, 4, 8, 12, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an ACR50 Response at Weeks 1, 2, 4, 8, 12, and 24
percentage of participantsPlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QD
Week 11.41.4107.2
Week 24.25.67.121.7
Week 44.215.318.623.2
Week 85.616.725.731.9
Week 1211.134.737.143.5
Week 24—33.338.644.9
SecondaryPercentage of Participants Achieving an ACR70 Response at Weeks 1, 2, 4, 8, 12, and 24

ACR70 response: 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

Time frame:
Weeks 1, 2, 4, 8, 12, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an ACR70 Response at Weeks 1, 2, 4, 8, 12, and 24
percentage of participantsPlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QD
Week 1001.41.4
Week 22.81.41.44.3
Week 41.48.35.711.6
Week 82.86.911.417.4
Week 122.88.318.613
Week 24—19.425.724.6
SecondaryACR N% Improvement (ACR-N) Response at Weeks 1, 2, 4, 8, 12, and 24

The ACR-N is the smallest percentage improvement in swollen and tender joints and the median of the remaining 5 core parameters, and is expected to be more sensitive to change than the ACR20, ACR50 or ACR70. It is a number varying between 0 and 100, with higher numbers indicating less severity of symptoms. Last observation carried forward (LOCF) algorithm was used (ie, to impute a missing value, the last preceding nonmissing value was used). All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

Time frame:
Weeks 1, 2, 4, 8, 12, and 24
Reported as:
Mean · percentage of improvement
ACR N% Improvement (ACR-N) Response at Weeks 1, 2, 4, 8, 12, and 24
percentage of improvementPlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QD
Week 16.79 ± 1.3411.66 ± 1.64112.84 ± 2.29116.8 ± 2.346
Week 210.79 ± 1.91717.11 ± 2.36216.06 ± 2.26127.01 ± 2.776
Week 412.03 ± 2.05825 ± 2.85224.06 ± 2.89832.21 ± 3.172
Week 813.35 ± 2.2430.46 ± 2.98632.66 ± 3.15439.24 ± 3.375
Week 1216.28 ± 2.72335.03 ± 3.17838.35 ± 3.53341 ± 3.477
Week 24—38.75 ± 3.74846.32 ± 3.29546.78 ± 3.648
SecondaryPercentage of Participants With Disease Activity Score 28 Joints Corrected for CRP (DAS28 (CRP)) European League Against Rheumatism (EULAR) Response at Weeks 1, 2, 4, 8, 12, and 24

DAS28 (CRP) was categorized into EULAR response categories (none, moderate, good) as follows: None = Actual DAS28 (CRP) ≤ 3.2, \> 3.2 to ≤ 5.1, or \> 5.1 AND Improvement in DAS28 (CRP) from baseline ≤ 6.0 or \> 0.6 to ≤ 1.2; Moderate = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline \> 0.6 to ≤ 1.2, Actual DAS28 (CRP) \> 3.2 to ≤ 5.1 or \> 5.1 AND Improvement in DAS28 (CRP) from baseline \> 1.2, or Actual DAS28 (CRP) \> 3.2 to ≤ 5.1 AND Improvement in DAS28 (CRP) from baseline \> 0.6 to ≤ 1.2; Good = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline \> 1.2. LOCF algorithm was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

Time frame:
Weeks 1, 2, 4, 8, 12, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Activity Score 28 Joints Corrected for CRP (DAS28 (CRP)) European League Against Rheumatism (EULAR) Response at Weeks 1, 2, 4, 8, 12, and 24
percentage of participantsPlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QD
Week 1: None72576349
Week 1: Moderate26403143
Week 1: Good1367
Week 2: None67444726
Week 2: Moderate31494664
Week 2: Good37710
Week 4: None58383922
Week 4: Moderate35474655
Week 4: Good7151623
Week 8: None54362412
Week 8: Moderate36395454
Week 8: Good10252135
Week 12: None49312014
Week 12: Moderate38465341
Week 12: Good14242745
Week 24: None—28910
Week 24: Moderate—364143
Week 24: Good—365046
SecondaryPercentage of Participants Achieving ACR/EULAR Remission at Weeks 2, 4, 8, 12, and 24

A participant's disease activity status can be defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and Patient Global Assessment of Disease Activity (cm) are all ≤ 1. Non-responder imputation was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

Time frame:
Weeks 4, 8, 12, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR/EULAR Remission at Weeks 2, 4, 8, 12, and 24
percentage of participantsPlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QD
Week 401.401.4
Week 80007.2
Week 121.41.44.34.3
Week 24—8.38.68.7
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 1, 2, 4, 8, 12, and 24

The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), Physician's Global Assessment of Disease Activity (in cm), and CRP (mg/dL). The SDAI was categorized as follows: • High disease activity: SDAI \> 26 • Moderate disease activity: 11 to 26 • Low disease activity: 3.3 to 11 • Remission: ≤ 3.3. LOCF algorithm was used. The SDAI total score ranges from 0 to approximately 86. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

Time frame:
Baseline and Weeks 1, 2, 4, 8, 12, and 24
Reported as:
Mean · units on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 1, 2, 4, 8, 12, and 24
units on a scalePlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QD
Baseline45.73 ± 1.478943.77 ± 1.560946.608 ± 1.653844.139 ± 1.5079
Change at Week 1-7.45 ± 1.55289.596 ± 1.2567-10.886 ± 1.6511-14.349 ± 1.4346
Change at Week 2-10.022 ± 1.371-12.194 ± 1.5982-13.172 ± 1.6209-18.27 ± 1.6934
Change at Week 4-10.927 ± 1.7771-17.57 ± 1.7653-18.862 ± 1.8073-21.288 ± 1.6619
Change at Week 8-12.452 ± 1.7748-20.144 ± 1.9425-23.119 ± 1.8041-25.556 ± 1.6949
Change at Week 12-12.574 ± 1.984-21.413 ± 1.7953-25.269 ± 1.9856-26.499 ± 1.7534
Change at Week 24—-23.16 ± 1.9364-30.983 ± 1.7732-29.564 ± 1.8583
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 1, 2, 4, 8, 12, and 24

The CDAI is the SDAI modified to exclude CRP and is the sum of the 4 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), and Physician's Global Assessment of Disease Activity (in cm). The CDAI was be categorized as follows: • High disease activity: \> 22 • Moderate disease activity: 10 to 22 • Mild disease activity: 2.8 to 10 • Remission: ≤ 2.8. LOCF algorithm was used. The CDAI total score ranges from 0 to approximately 76. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

Time frame:
Baseline and Weeks 1, 2, 4, 8, 12, and 24
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 1, 2, 4, 8, 12, and 24
units on a scalePlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QD
Baseline42.168 ± 1.327241.438 ± 1.477744.052 ± 1.538341.869 ± 1.423
Change at Week 1-6.867 ± 1.4538-9.226 ± 1.1545-9.853 ± 1.5591-13.148 ± 1.4085
Change at Week 2-9.861 ± 1.1909-11.803 ± 1.5275-12.306 ± 1.5618-16.999 ± 1.702
Change at Week 4-10.743 ± 1.7184-16.701 ± 1.7003-17.654 ± 1.6987-20.044 ± 1.6396
Change at Week 8-12.071 ± 1.6982-19.087 ± 1.8583-21.703 ± 1.7491-24.228 ± 1.6479
Change at Week 1211.696 ± 1.8752-21.019 ± 1.7168-24.044 ± 1.9665-25.071 ± 1.742
Change at Week 24—-22.278 ± 1.8637-29.502 ± 1.6928-28.102 ± 1.818
SecondaryChange From Baseline in Quality of Life Using the Functional Assessment of Chronic Illness Therapy (FACIT) at Weeks 4, 12, and 24

FACIT-Fatigue scale is a 13-item questionnaire, each scored on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated that are scored reversely), the greater the fatigue. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score), with a higher score indicating a better quality of life. LOCF algorithm was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life Using the Functional Assessment of Chronic Illness Therapy (FACIT) at Weeks 4, 12, and 24
units on a scalePlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QD
Baseline25.1 ± 1.1225.1 ± 1.2824.8 ± 1.1324.8 ± 1.16
Change at Week 41.4 ± 1.147.2 ± 1.37.2 ± 1.268.5 ± 1.3
Change at Week 123.9 ± 1.239.5 ± 1.4310.2 ± 1.2111.2 ± 1.44
Change at Week 24—10 ± 1.4311.3 ± 1.213.7 ± 1.38
SecondaryChange From Baseline in Quality of Life Using the Short Form-36 (SF-36) Scores at Weeks 4, 12, and 24

The SF-36 is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status. Two summary scale scores were computed based on weighted combinations of the 8 domain scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). LOCF algorithm was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life Using the Short Form-36 (SF-36) Scores at Weeks 4, 12, and 24
units on a scalePlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QD
PCS at Baseline31.1 ± 0.698831.05 ± 0.81630.946 ± 0.763131.804 ± 0.8965
PCS Change at Week 42.1 ± 0.725.7 ± 1.045.1 ± 0.926.8 ± 0.92
PCS Change at Week 123 ± 0.897.1 ± 1.117.8 ± 1.048.6 ± 1.09
PCS Change at Week 24—6.9 ± 1.1610 ± 1.179.7 ± 1.09
MCS at Baseline40.525 ± 1.305342.793 ± 1.324741.185 ± 1.234742.613 ± 1.1674
MCS at Week 42.1 ± 1.13.6 ± 1.095.3 ± 1.043.9 ± 1.16
MCS at Week 122.7 ± 1.044.9 ± 1.186.9 ± 1.046.8 ± 1.33
MCS at Week 24—5.1 ± 1.277.7 ± 1.168.5 ± 1.12

Adverse events

Collected over Baseline through end of study drug treatment (average exposure: 161.0 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/72 (0%)1/72 (1.4%)9/72 (12.5%)
GLPG0634 50 mg QD0/72 (0%)2/72 (2.8%)14/72 (19.4%)
GLPG0634 100 mg QD0/85 (0%)3/85 (3.5%)21/85 (24.7%)
GLPG0634 200 mg QD0/69 (0%)3/69 (4.3%)16/69 (23.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QD
Back painMusculoskeletal and connective tissue disorders0/720/720/851/69
OsteoarthritisMusculoskeletal and connective tissue disorders0/720/720/851/69
PneumoniaInfections and infestations0/720/720/851/69
Humerus fractureInjury, poisoning and procedural complications0/721/720/850/69
Rheumatoid arthritisMusculoskeletal and connective tissue disorders1/720/720/850/69
GastroenteritisInfections and infestations0/721/720/850/69
VertigoEar and labyrinth disorders0/720/721/850/69
CellulitisInfections and infestations0/720/721/850/69
Pyelonephritis chronicInfections and infestations0/720/721/850/69
Most frequent other events
Most frequent other events
EventPlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QD
Urinary tract infectionInfections and infestations1/723/727/854/69
HypercholesterolaemiaMetabolism and nutrition disorders3/724/725/851/69
HypertriglyceridaemiaMetabolism and nutrition disorders1/722/725/851/69
AnaemiaBlood and lymphatic system disorders0/721/720/854/69
Upper respiratory tract infectionInfections and infestations2/722/724/854/69
HypertensionVascular disorders4/723/721/852/69
HeadacheNervous system disorders1/724/721/853/69

Baseline characteristics

Safety population included all participants who were randomized and received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)PlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDTotal
Mean51.5 (20 to 77)52.1 (18 to 79)52.8 (22 to 78)51.8 (25 to 79)52.1 (18 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDTotal
Female56625360231
Male161017952
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDTotal
Hispanic or Latino2523252598
Not Hispanic or Latino47494544185
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDTotal
American Indian or Alaska Native00000
Asian01001
Native Hawaiian or Other Pacific Islander10001
Black or African American11103
White53535354213
More than one race1717161565
Unknown or Not Reported00000
Rheumatoid Arthritis (RA) duration
Rheumatoid Arthritis (RA) duration(years)PlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDTotal
Mean9.46 (0.7 to 28.9)8.63 (0.5 to 23.4)8.57 (0.5 to 33.7)8.68 (0.5 to 49.6)8.84 (0.5 to 49.6)
C-reactive protein (CRP) at Baseline
C-reactive protein (CRP) at Baseline(milligram per liter (mg/L))PlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDTotal
Mean35.26 (1 to 175)24.67 (1 to 162.9)25.55 (1.6 to 244.1)23.16 (1 to 91.3)27.21 (1.0 to 244.1)
Corrected tender joint count based on 68 joints (TJC68) at Baseline
Corrected tender joint count based on 68 joints (TJC68) at Baseline(joint count)PlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDTotal
Mean25.226 (8 to 63)25.58 (9 to 64)27.195 (8 to 65)26.242 (8 to 65.94)26.051 (8 to 65.94)
Corrected swollen joint count based on 66 joints (SJC66) at Baseline
Corrected swollen joint count based on 66 joints (SJC66) at Baseline(joint count)PlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDTotal
Mean15.98 (7 to 38)16.969 (7 to 48)18.653 (6 to 56)15.74 (6 to 46)16.834 (6 to 56)
08

Study locations

82 sites
  • Artho Care, Arthritis Care & Research P.C.
    Gilbert, Arizona, United States
  • Arizona Arthritis & Rheumatology Research PLLC
    Mesa, Arizona, United States
  • Arizona Arthritis Rheum Res
    Phoenix, Arizona, United States
  • Little Rock Diagnostic Clinic
    Little Rock, Arkansas, United States
  • C.V. Mehta MD Medical Corp.
    Hemet, California, United States
  • Center for Innovative Therapy Division of Rheumatology, UCSD
    La Jolla, California, United States
  • Desert Medical Advances
    Palm Desert, California, United States
  • Infosphere Clinical Research, Inc.
    West Hills, California, United States
  • Lovelace Scientific Resources
    Venice, Florida, United States
  • Arthritis Center of North GA
    Gainesville, Georgia, United States
  • The Arthritis Center
    Springfield, Illinois, United States
  • Klein and Associates MD
    Hagerstown, Maryland, United States
  • Private practice
    Lansing, Michigan, United States
  • Arthritis Center of Reno
    Reno, Nevada, United States
  • New Jersey Physicians, LLC
    Clifton, New Jersey, United States
  • Health research of Oklahoma
    Oklahoma City, Oklahoma, United States
  • Altoona Center Clin Research
    Duncansville, Pennsylvania, United States
  • Low Country Rheumatology, PA
    Charleston, South Carolina, United States
  • Arthritis Clinic
    Jackson, Tennessee, United States
  • Austin Rheumatology Research PA
    Austin, Texas, United States
  • Pioneer Research Solutions Inc
    Houston, Texas, United States
  • Centro de Investigaciones Medicas Lanus
    Lanus, Argentina
  • Instituto Centralizado de Asistencia e investigacion Clinica Integral
    Rosario, Argentina
  • Centro Médico Privado de Reumatología
    Tucuman, Argentina
  • Royal Prince Alfred Hospital
    Camperdown, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Australia
  • Rheumazentrum Favoriten
    Wien, Austria
  • "Multiprofile Hospital for Active Treatment - Kaspela" LTD
    Plovdiv, Bulgaria
  • Clinic of Rheumatology MHAT
    Sofia, Bulgaria
  • Hospital Regional "Guillermo Grant Benavente"
    Concepcion, Chile
  • Private Office
    Temuco, Chile
  • Fundación del Caribe para la Investigación Biomédica BIOS
    Barranquilla, Colombia
  • Centro Integral de Reumatologia SAS
    Bogota, Colombia
  • Cirei Sas
    Bogota, Colombia
  • Idearg S.A.S.
    Bogota, Colombia
  • Medicity S.A.S.
    Bucaramanga, Colombia
  • Preventive Care Ltda
    Chia, Colombia
  • Schlossparkklinik - Akad. Lehrkrankenhaus Charite
    Berlin, Germany
  • Schwerpunktpraxis fuer Rheumatologie
    Hamburg, Germany
  • Clinica Médica Especializada en Medicina Interna
    Guatemala City, Guatemala
  • Reuma S.A.
    Guatemala City, Guatemala
  • Reuma-Centro
    Guatemala City, Guatemala
  • DRC
    Balatonfüred, Hungary
  • Qualiclinic Ltd
    Budapest, Hungary
  • Revita Clinic
    Budapest, Hungary
  • Csolnoky Ferenc County Hospital
    Veszprem, Hungary
  • L. Atikes doktorats
    Liepaja, Latvia
  • "Bruninieku" Polyclinic
    Riga, Latvia
  • Arké Estudios Clínicos S.A. de C.V.
    Mexico, Mexico
  • Centro Medico Dalinde
    Mexico, Mexico
  • Clinstile, S.A. de C.V.
    Mexico, Mexico
  • Mexico Centre for Clinical Research
    Mexico, Mexico
  • Hospital Universitario
    Monterrey, Mexico
  • Hospital de Especialidades
    Oaxaca, Mexico
  • IMSP Institutul de Cardiologie
    Chisinau, Moldova, Republic of
  • North Shore hospital
    Auckland, New Zealand
  • Timaru Rheumatology Studies
    Timaru, New Zealand
  • Silesiana Centrum Medyczne
    Bytom, Poland
  • Centrum Kliniczno
    Elblag, Poland
  • Medica Pro Familia Sp. z o.o. S.K.A.
    Katowice, Poland
  • Nowomed
    Krakow, Poland
  • Nzoz "Dobry Lekarz"
    Krakow, Poland
  • NZOZ Przychodnia Lekarska "Eskulap"
    Skierniewice, Poland
  • NZOZ Medicus Bonus
    Sroda Wielkopolska, Poland
  • AMED Medical Center
    Warsaw, Poland
  • Ars Rheumatica Sp. Z.o.o.
    Warszawa, Poland
  • Wojewodzki Szpital Specjalistyczny we Wroclawiu
    Wroclaw, Poland
  • Ianuli Med Consult SRL
    Bucharest, Romania
  • Sana Medical Center
    Bucuresti, Romania
  • Spitalul Clinic Sfanta Maria
    Bucuresti, Romania
  • Emergency County Hospital
    Galati, Romania
  • Orenburg State Medical Academy
    Orenburg, Russian Federation
  • GUZ "Regional Clinical Hospital"
    Saratov, Russian Federation
  • Vladimir Reg Clin Hosp
    Vladimir, Russian Federation
  • Hospital General Elche
    Elche, Spain
  • Consorci Sanitari Parc Tauli
    Sabadell, Spain
  • CICEC S.L.P Hospital Ntra.Sra.de la Esperanza
    Santiago De Compostella, Spain
  • V. Gusak Institute of Urgent and Recovery Surgery
    Donetsk, Ukraine
  • City Hospital #8
    Kharkiv, Ukraine
  • Municipal Hospital
    Kherson, Ukraine
  • Central Outpatient Hospital of Deanyanskyy Distric
    Kiev, Ukraine
  • Regional Clinical Hospital
    Vinnytsya, Ukraine
09

References and documents

Publications

  • Combe B, Besuyen R, Gomez-Centeno A, Matsubara T, Sancho Jimenez JJ, Yin Z, Buch MH. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis. Rheumatol Ther. 2023 Feb;10(1):35-51. doi: 10.1007/s40744-022-00494-1. Epub 2022 Oct 7. PubMed 36205910 ↗
  • Tarrant JM, Galien R, Li W, Goyal L, Pan Y, Hawtin R, Zhang W, Van der Aa A, Taylor PC. Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials. Rheumatol Ther. 2020 Mar;7(1):173-190. doi: 10.1007/s40744-019-00192-5. Epub 2020 Jan 7. PubMed 31912462 ↗
  • Kavanaugh A, Kremer J, Ponce L, Cseuz R, Reshetko OV, Stanislavchuk M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017 Jun;76(6):1009-1019. doi: 10.1136/annrheumdis-2016-210105. Epub 2016 Dec 19. PubMed 27993828 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Mar 2015, 16 months.

Results were first posted in Nov 2020, 5 years 8 months after primary completion. A results delay was requested in Apr 2016.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 16 months is close to that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2013
First posted
Jul 10, 2013
StartActual
Oct 8, 2013
Primary completionActual
Mar 5, 2015
CompletionActual
May 29, 2015
Results delay requested
Apr 18, 2016
Results first posted
Nov 19, 2020
Last update
Dec 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01894516
Lead sponsor
Galapagos NV
Responsible party
Sponsor
First posted
Jul 10, 2013
Start date
Oct 8, 2013
Primary completion
Mar 5, 2015
Completion
May 29, 2015
Results posted
Nov 19, 2020
Last update
Dec 16, 2020

Study contacts

Galapagos Study Director
study director · Galapagos NV

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion